Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Benson Hill, Inc.BHIL · Entity 87189 | Director | July 18, 2024 | August 01, 2024 |
| QualTek Services Inc.ROCRU · Entity 115163 | Director | March 05, 2021 | March 08, 2021 |
| Reservoir Media, Inc.ROCCU · Entity 5296 | Director | December 15, 2020 | December 17, 2020 |
| Roth CH Acquisition I CoROCHU · Entity 148912 | Director | May 07, 2020 | May 11, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Benson Hill, Inc.
Report date July 18, 2024 · Filed August 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | Direct | 6,481 |
Reported balance
After 2024-07-18 transaction · row 1
1 source rowRow 1 · 2024-07-18 · Exercise / conversion · Acquired 4,352 · Balance 6,481 F1: Represents vesting of restricted stock units granted on August 11, 2023 under the Issuer's 2021 Omnibus Incentive Plan. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-07-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-07-18 · Exercise / conversion · Disposed 4,352 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1: Represents vesting of restricted stock units granted on August 11, 2023 under the Issuer's 2021 Omnibus Incentive Plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,675 |
Reported balance
After 2024-07-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-07-18 · Grant · Acquired 10,675 · Balance 10,675 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3: Granted on July 18, 2024 (the "Grant Date") under the Issuer's 2021 Omnibus Incentive Plan. The restricted stock units vest in full on the earlier of the first anniversary of the Grant Date or the Issuer's 2025 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents vesting of restricted stock units granted on August 11, 2023 under the Issuer's 2021 Omnibus Incentive Plan.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: Granted on July 18, 2024 (the "Grant Date") under the Issuer's 2021 Omnibus Incentive Plan. The restricted stock units vest in full on the earlier of the first anniversary of the Grant Date or the Issuer's 2025 Annual Meeting of Stockholders.
QualTek Services Inc.
Report date March 05, 2021 · Filed March 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,233 |
Reported balance
After 2021-03-05 transaction · row 1
1 source rowRow 1 · 2021-03-05 · Purchase · Acquired 5,000 · Balance 40,233 F1: The reporting person acquired units, consisting of shares and warrants. |
| Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 1,250 |
Reported balance
After 2021-03-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-05 · Purchase · Acquired 1,250 · Balance 1,250 F1: The reporting person acquired units, consisting of shares and warrants. F2: The warrants become exercisable 30 days after the consummation of the registrant's initial business combination. F3: The warrants expire 5 years after the completion of the registrant's initial business combination or earlier upon redemption or liquidation, as described in the registrant's prospectus filed with the SEC. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person acquired units, consisting of shares and warrants.
F2: The warrants become exercisable 30 days after the consummation of the registrant's initial business combination.
F3: The warrants expire 5 years after the completion of the registrant's initial business combination or earlier upon redemption or liquidation, as described in the registrant's prospectus filed with the SEC.
Reservoir Media, Inc.
Report date December 15, 2020 · Filed December 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,189 |
Reported balance
After 2020-12-15 transaction · row 1
1 source rowRow 1 · 2020-12-15 · Purchase · Acquired 7,699 · Balance 88,189 F1: The reporting person acquired units, consisting of shares and warrants. |
| Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 3,849 |
Reported balance
After 2020-12-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-15 · Purchase · Acquired 3,849 · Balance 3,849 F1: The reporting person acquired units, consisting of shares and warrants. F2: The warrants become exercisable 30 days after the consummation of the registrant's initial business combination. F3: The warrants expire 5 years after the completion of the registrant's initial business combination or earlier upon redemption or liquidation, as described in the registrant's prospectus filed with the SEC. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person acquired units, consisting of shares and warrants.
F2: The warrants become exercisable 30 days after the consummation of the registrant's initial business combination.
F3: The warrants expire 5 years after the completion of the registrant's initial business combination or earlier upon redemption or liquidation, as described in the registrant's prospectus filed with the SEC.
Roth CH Acquisition I Co
Report date May 07, 2020 · Filed May 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,658 |
Reported balance
After 2020-05-07 transaction · row 1
1 source rowRow 1 · 2020-05-07 · Purchase · Acquired 10,000 · Balance 85,658 F1: The reporting person acquired units, consisting of shares and warrants. |
| Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 7,500 |
Reported balance
After 2020-05-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-07 · Purchase · Acquired 7,500 · Balance 7,500 F1: The reporting person acquired units, consisting of shares and warrants. F2: The warrants become exercisable on the later of (i) the completion of the registrant's initial business combination and (ii) 12 months from the closing of the registrant's initial public offering. F3: The warrants expire 5 years after the completion of the registrant's initial business combination or earlier upon redemption or liquidation, as described in the registrant's prospectus filed with the SEC. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person acquired units, consisting of shares and warrants.
F2: The warrants become exercisable on the later of (i) the completion of the registrant's initial business combination and (ii) 12 months from the closing of the registrant's initial public offering.
F3: The warrants expire 5 years after the completion of the registrant's initial business combination or earlier upon redemption or liquidation, as described in the registrant's prospectus filed with the SEC.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LIFECORE BIOMEDICAL, INC. \DE\
Report date May 23, 2019 · Filed August 06, 2019 · Amendment
Section 16 reporting ended · disclosed 2019-08-06. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 155,015 |
Last balance in matching sequence
After 2019-05-23 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2019-05-23 · Exercise / conversion · Acquired 71,575 · Balance 179,765 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2: Original filing on 5/23/19 and subsequent amendment filing on 5/29/19 inadvertently reported incorrect total number of shares. Row 2 · 2019-05-23 · Tax withholding · Disposed 24,750 · Balance 155,015 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2: Original filing on 5/23/19 and subsequent amendment filing on 5/29/19 inadvertently reported incorrect total number of shares. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2019-05-23 | Direct | 71,575 |
Reported balance
After 2019-05-23 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2019-05-23 · Exercise / conversion · Disposed 71,575 · Balance 71,575 F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F3: Restricted Stock Unit awards granted on July 21,2016, October 19,2017 and July 22, 2018 have accelerated due to resignation on May 23, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis.
F2: Original filing on 5/23/19 and subsequent amendment filing on 5/29/19 inadvertently reported incorrect total number of shares.
F3: Restricted Stock Unit awards granted on July 21,2016, October 19,2017 and July 22, 2018 have accelerated due to resignation on May 23, 2019.
TIGO ENERGY, INC.
Report date May 23, 2023 · Filed May 25, 2023
Section 16 reporting ended · disclosed 2023-05-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,549 |
Reported balance
After 2023-05-23 transaction · row 1
1 source rowRow 1 · 2023-05-23 · Sale · Disposed 20,485 · Balance 12,549 F1: The reporting person disposed of (i) 16,287 shares of common stock and (ii) 4,198 units, each unit consisting of one share of common stock and one-half of one warrant, for total consideration of $22,770.75. |
| Warrants to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 185 |
Reported balance
After 2023-05-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-23 · Sale · Disposed 2,099 · Balance 185 F1: The reporting person disposed of (i) 16,287 shares of common stock and (ii) 4,198 units, each unit consisting of one share of common stock and one-half of one warrant, for total consideration of $22,770.75. F2: The warrants become exercisable 30 days after the consummation of the registrant's initial business combination. F3: The warrants expire 5 years after the completion of the registrant's initial business combination or earlier upon redemption or liquidation, as described in the registrant's prospectus filed with the SEC. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person disposed of (i) 16,287 shares of common stock and (ii) 4,198 units, each unit consisting of one share of common stock and one-half of one warrant, for total consideration of $22,770.75.
F2: The warrants become exercisable 30 days after the consummation of the registrant's initial business combination.
F3: The warrants expire 5 years after the completion of the registrant's initial business combination or earlier upon redemption or liquidation, as described in the registrant's prospectus filed with the SEC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 24, 2017 Filed Oct 24, 2017 21:39 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | SaleCommon Stock | 7,199 | $13.06 | $94,018.94 |
DisclosureSEC source: 0001437749-17-017538 · rdgdoc.xml · nonDerivative · entry 2 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,818 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 23, 2017 Filed Oct 24, 2017 21:39 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | SaleCommon Stock | 200 | $13.20 | $2,640.00 |
DisclosureSEC source: 0001437749-17-017538 · rdgdoc.xml · nonDerivative · entry 1 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,017 Read SEC document |
| October 20, 2017 Filed Oct 23, 2017 20:18 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRight to Buy Restricted Stock Unit (RSU) · Derivative | 23,703 | $13.00 Strike: $13.00 | $308,139.00 |
DisclosureSEC source: 0001437749-17-017445 · rdgdoc.xml · derivative · entry 5 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,703 Underlying: Common Stock · 23,703 shares Expires 2017-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Restricted Stock Units will vest on the 3rd anniversary of the grant date and will be automatically settled in shares of common stock subject to vesting at a rate of 1 share per unit. Read SEC document |
| October 20, 2017 Filed Oct 23, 2017 20:18 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Tax withholdingCommon Stock | 8,904 | $13.00 | $115,752.00 |
DisclosureSEC source: 0001437749-17-017445 · rdgdoc.xml · nonDerivative · entry 2 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,217 Read SEC document |
| October 20, 2017 Filed Oct 23, 2017 20:18 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionCommon Stock | 23,703 | $13.00 | $308,139.00 |
DisclosureSEC source: 0001437749-17-017445 · rdgdoc.xml · nonDerivative · entry 1 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2017 Filed Oct 23, 2017 20:18 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRight to Buy Restricted Stock Unit (RSU) · Derivative | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-17-017445 · rdgdoc.xml · derivative · entry 4 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2020-10-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · derivative.exercise_date: Restricted Stock Units will vest on the 3rd anniversary of the grant date and will be automatically settled in shares of common stock subject to vesting at a rate of 1 share per unit. Read SEC document |
| October 19, 2017 Filed Oct 23, 2017 20:18 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 45,000 | $12.65 Strike: $12.65 | $569,250.00 |
DisclosureSEC source: 0001437749-17-017445 · rdgdoc.xml · derivative · entry 3 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,000 Underlying: Common Stock · 45,000 shares Expires 2024-10-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 19, 2017 22:09 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionNonqualified Stock Options (Right to Buy) · Derivative | 16,714 | $0.00 Strike: $5.63 | $0.00 |
DisclosureSEC source: 0001437749-17-009691 · rdgdoc.xml · derivative · entry 6 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,000 Underlying: Common Stock · 16,714 shares Expires 2017-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 19, 2017 22:09 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 20,786 | $0.00 Strike: $5.63 | $0.00 |
DisclosureSEC source: 0001437749-17-009691 · rdgdoc.xml · derivative · entry 5 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496,714 Underlying: Common Stock · 20,786 shares Expires 2017-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 19, 2017 22:09 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Tax withholdingCommon Stock | 10,697 | $13.30 | $142,270.10 |
DisclosureSEC source: 0001437749-17-009691 · rdgdoc.xml · nonDerivative · entry 4 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,418 Read SEC document |
| May 18, 2017 Filed May 19, 2017 22:09 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionCommon Stock | 16,714 | $5.63 | $94,099.82 |
DisclosureSEC source: 0001437749-17-009691 · rdgdoc.xml · nonDerivative · entry 3 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 19, 2017 22:09 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Tax withholdingCommon Stock | 8,798 | $13.30 | $117,013.40 |
DisclosureSEC source: 0001437749-17-009691 · rdgdoc.xml · nonDerivative · entry 2 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,401 Read SEC document |
| May 18, 2017 Filed May 19, 2017 22:09 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionCommon Stock | 20,786 | $5.63 | $117,025.18 |
DisclosureSEC source: 0001437749-17-009691 · rdgdoc.xml · nonDerivative · entry 1 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2016 Filed Oct 24, 2016 23:41 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRight to Buy Restricted Stock Unit (RSU) · Derivative | 23,703 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-16-040133 · rdgdoc.xml · derivative · entry 2 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,703 Underlying: Common Stock · 23,703 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F1 · derivative.expiration_date: Restricted Stock Units will vest on the 1st anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
| October 20, 2016 Filed Oct 24, 2016 23:41 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LNDC · Entity 6447 | Exercise / conversionRight to Buy Restricted Stock Unit (RSU) · Derivative | 23,703 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-16-040133 · rdgdoc.xml · derivative · entry 1 Hemmeter Molly · CIK 0001465272 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,703 Underlying: Common Stock · 23,703 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F2 · price: The restricted stock units convert into common stock of Landec Corporation on a 1 for 1 basis. F3 · derivative.expiration_date: Restricted Stock Units will vest on the 2nd anniversary of the grant date and will be automatically settled in shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.